OBJECTIVE: We investigated clinical outcomes after treatment of coronary bifurcation lesions with second generation drug eluting stents (DES). DESIGN: Post hoc analysis of a randomised, multicentre, non-inferiority trial. SETTING: Multicentre study. PATIENTS: All comers study with minimal exclusion criteria. INTERVENTIONS: Patients were treated with either zotarolimus or everolimus eluting stents. The patient population was divided according to treatment of bifurcation or non-bifurcation lesions and clinical outcomes were compared between groups. MAIN OUTCOMES MEASURES: Clinical outcomes within 2-year follow-up. RESULTS:A total of 2265 patients were included in the present analysis. Two-year follow-up data were available in 2223 patients: 1838 patients in the non-bifurcation group and 385 patients in the bifurcation group. At 2-year follow-up the bifurcation and the non-bifurcation lesion groups showed no significant differences in terms of cardiac death (2.3 vs 2.1, p=0.273), target lesion failure (9.7% vs 13.8%, p=0.255), major adverse cardiac events (11.5% vs 15.1%, p=0.305), target lesion revascularisation (4.7% vs 6.0%, p=0.569), and definite or probable stent thrombosis (1.6% vs 1.8%, p=0.419). CONCLUSIONS: The use of second generation DES for the treatment of coronary bifurcation lesions was associated with similar long term mortality and clinical outcomes compared with non-bifurcation lesions.
RCT Entities:
OBJECTIVE: We investigated clinical outcomes after treatment of coronary bifurcation lesions with second generation drug eluting stents (DES). DESIGN: Post hoc analysis of a randomised, multicentre, non-inferiority trial. SETTING: Multicentre study. PATIENTS: All comers study with minimal exclusion criteria. INTERVENTIONS:Patients were treated with either zotarolimus or everolimus eluting stents. The patient population was divided according to treatment of bifurcation or non-bifurcation lesions and clinical outcomes were compared between groups. MAIN OUTCOMES MEASURES: Clinical outcomes within 2-year follow-up. RESULTS: A total of 2265 patients were included in the present analysis. Two-year follow-up data were available in 2223 patients: 1838 patients in the non-bifurcation group and 385 patients in the bifurcation group. At 2-year follow-up the bifurcation and the non-bifurcation lesion groups showed no significant differences in terms of cardiac death (2.3 vs 2.1, p=0.273), target lesion failure (9.7% vs 13.8%, p=0.255), major adverse cardiac events (11.5% vs 15.1%, p=0.305), target lesion revascularisation (4.7% vs 6.0%, p=0.569), and definite or probable stent thrombosis (1.6% vs 1.8%, p=0.419). CONCLUSIONS: The use of second generation DES for the treatment of coronary bifurcation lesions was associated with similar long term mortality and clinical outcomes compared with non-bifurcation lesions.
Authors: K Gert van Houwelingen; Liefke C van der Heijden; Ming Kai Lam; Marlies M Kok; Marije M Löwik; J W Louwerenburg; Gerard C M Linssen; Maarten J IJzerman; Carine J M Doggen; Clemens von Birgelen Journal: Heart Vessels Date: 2016-01-08 Impact factor: 2.037
Authors: Liefke C van der Heijden; Marlies M Kok; Ming Kai Lam; Peter W Danse; Alexander R Schramm; Gillian A J Jessurun; R Melvyn Tjon Joe Gin; K Gert van Houwelingen; Raymond W M Hautvast; Gerard C M Linssen; Hanim Sen; Marije M Löwik; Maarten J IJzerman; Carine J M Doggen; Clemens von Birgelen Journal: Clin Res Cardiol Date: 2015-09-02 Impact factor: 5.460
Authors: Paul D Morris; Rebecca Gosling; Alex Rothman; Javaid Iqbal; Claudio Chiastra; Monika Colombo; Francesco Migliavacca; Amerjeet Banning; Julian P Gunn Journal: Can J Cardiol Date: 2019-08-30 Impact factor: 5.223